Abstract C092: Axl inhibitor TP-0903 augments chemo- and immunotherapy efficacy in pancreatic cancer
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-c092
Abstract: Pancreatic cancer is the 3rd leading cause of cancer-related deaths in the United States with a 5-year survival less than 9%. Resistance to standard therapy and limited response to immune checkpoint blockade due to the… read more here.
Keywords: axl inhibitor; inhibitor 0903; cancer; 0903 augments ... See more keywords